NewsSource: EClinCloud

EClinCloud Shares Practical AI Implementation: Empowering All Teams Internally and the Full Platform Externally

2 min readEClinCloud Editorial Team
640.png

Source: EClinCloud. Author: EClinCloud.

640.png
On March 21, the first 2026 meeting of the Clinical Trial Contract Research Organization Branch (hereinafter referred to as the "CRO Branch") of the China Pharmaceutical Quality Management Association was successfully held in Changsha. Executives from companies including R&G PharmaStudies and Boji Medical, along with nearly 50 representatives from 30 member organizations across the industry, attended the meeting.







EClinCloud Shares Practical AI Implementation


Centered on the topic "Company Experiences and Challenges in AI Deployment," the meeting aimed to move the industry from AI literacy to deeper awareness and ultimately to practical application, achieving effective adoption of AI technology across the industry in a pivotal year.


As the CRO Branch's third dedicated AI-themed meeting, Dr. Qin Long, Founder and CEO of EClinCloud, once again shared AI-related implementation practices.


Article illustration


From two perspectives—"enabling internal teams" and "enabling clients"—Dr. Qin Long introduced EClinCloud's AI exploration from proprietary algorithms to AI agents: driving efficiency gains across all internal functions, including product, R&D, medical, and commercial teams, while delivering platform-wide AI capabilities externally to support intelligent upgrades across clients' full clinical trial lifecycle.


The presentation offered industry partners a complete perspective from technology R&D to real-world scenario deployment. During the meeting, participants also held lively discussions on practical AI implementation and organizational change in clinical trials, focusing on the application prospects of intelligent tools for improving study site selection and participant recruitment efficiency, as well as practical pathways for companies advancing AI strategies.


Article illustration


EClinCloud will also continue to deepen the practical application of AI technology in clinical trial scenarios, using internalized capabilities to drive external value and working alongside industry peers to advance collaborative, AI-enabled development.


*This article is reposted from the WeChat Official Account CROU.








About EClinCloud


EClinCloud is a leading AI company in the clinical research industry, leveraging AI to build an integrated intelligent clinical cloud platform and endpoint assessment technologies. It provides global pharmaceutical companies and research institutions with technology products including eCOA, CTMS, eTMF, EDC, RTSM, IRC, and RM, as well as scale management, linguistic validation, rater training, and data quality analysis services to build efficient and precise digital solutions. Relying on AI predictive models and an intelligent data platform, it dynamically evaluates and helps improve the success rate of drug clinical trials, helping shorten drug and medical device R&D cycles for the benefit of patients.







Article illustration



















Read the original WeChat article

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.